Castle Biosciences Inc (CSTL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Castle Biosciences Inc (CSTL) stock forecast summary
Our AI ranks Castle Biosciences Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Castle Biosciences Inc is a small-cap company with a market capitalization of $976M. It ranks number 16 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast. Its Gross Margin of 77.3% is the highest of the 16 peers that report one.
For CSTL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 34.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CSTL included.
Follow CSTL freeCSTL price chart and AI forecast
How CSTL ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Castle Biosciences Inc (CSTL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | CSTL | Rank |
|---|---|---|
| Market Cap | $976M | 16/29 |
| P/B Ratio | 2.08x | 13/22 |
| EPS | $-1.05 | – |
| Book Value/Share | $15.39 | – |
| Revenue/Share | $11.70 | – |
| FCF/Share | $-0.02 | – |
Profitability & Margins
| Metric | CSTL | Rank |
|---|---|---|
| ROE | -4.1% | 6/14 |
| ROA | -3.5% | 7/20 |
| ROIC | -6.4% | 11/24 |
| Gross Margin | 77.3% | 1/16 |
| Operating Margin | -9.0% | 10/23 |
| Net Margin | -5.4% | 7/17 |
| EBT Margin | -9.0% | 10/23 |
| Tax Rate | -0.7% | – |
Financial Health
| Metric | CSTL | Rank |
|---|---|---|
| Current Ratio | 6.04x | 8/26 |
| Quick Ratio | 5.85x | 4/11 |
| D/E Ratio | 0.19x | 14/22 |
| Financial Leverage | 1.19x | 14/22 |
| Interest Coverage | -16.6x | 12/23 |
| Working Capital | $285M | 13/26 |
Cash Flow
| Metric | CSTL | Rank |
|---|---|---|
| Operating Cash Flow | $43M | 10/27 |
| Free Cash Flow | -$490K | 9/17 |
| Capital Spending | -$43M | 12/17 |
| OCF Growth YoY | -31.8% | 7/7 |
| FCF Growth YoY | -101.4% | 5/5 |
| FCF/Sales | -0.1% | 9/16 |
| CapEx/Sales | 12.1% | 4/16 |
Operational Efficiency
| Metric | CSTL | Rank |
|---|---|---|
| Asset Turnover | 0.64x | 9/18 |
| Receivables Turnover | 7.4x | 9/19 |
| Inventory Turnover | 7.7x | 4/7 |
| Fixed Assets Turnover | 3.4x | 12/17 |
| Days Sales Outstanding | 49 days | 11/19 |
| Days Inventory | 48 days | 4/7 |
| Payables Period | 43 days | 9/14 |
| Cash Conversion Cycle | 53 days | 5/6 |
Income Statement
| Metric | CSTL | Rank |
|---|---|---|
| Total Revenue | $357M | 10/19 |
| Operating Income | -$32M | 19/26 |
| Net Income | -$19M | 10/20 |
| R&D Expense | $55M | 11/20 |
| SG&A Expense | $244M | 12/20 |
| Cost of Goods Sold | $81M | 7/15 |
Dividend & Shareholder Information
| Metric | CSTL | Rank |
|---|---|---|
| Shares Outstanding | 31M | – |
| EPS Growth | -328.3% | 6/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $341M | 60.8% of assets |
| Cash & Short-term Investments | $62M | 11.1% of assets |
| Accounts Receivable | $48M | 8.6% of assets |
| Inventory | $11M | 1.9% of assets |
| Total Liabilities | $91M | 16.2% of assets |
| Short-term Debt | $47M | 8.3% of assets |
CSTL quarterly financials and insider trading
Castle Biosciences Inc (CSTL) industry peers
Companies classified under the same SEC industry code as Castle Biosciences Inc (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| CSTL Castle Biosciences Inc | ▲ | $976M |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▼ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▲ | $2.14B |
| PSNL Personalis, Inc. | ▲ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▲ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▼ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▼ | $260K |
| RNLXY Renalytix Plc | ▶ | N/A |
Where CSTL sits on the market map
Castle Biosciences Inc (CSTL) stock news
Loading...
Castle Biosciences Inc (CSTL) stock forecast FAQ
What is the Castle Biosciences Inc (CSTL) stock forecast?
Our AI ranks Castle Biosciences Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Castle Biosciences Inc stock predictions?
For CSTL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 34.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Castle Biosciences Inc forecasts updated?
Castle Biosciences Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Castle Biosciences Inc's industry peers?
30 issuers in our coverage, CSTL included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.